Oncology Phase 3 Readout Calendar
Industry-sponsored oncology trials with primary completion in the next 12 months or last 12 months.
Data last updated November 12, 2026 · source: ClinicalTrials.gov
All areas OncologyImmunologyMetabolicCNSCardiovascularRespiratoryRare DiseaseInfectious DiseaseMusculoskeletalDermatologyOphthalmology
113
Next 6 months
218
Next 12 months
56
Results posted
1,011
Phase 3 Oncology
What you can answer with this page
A confidence-graded calendar of every industry Phase 3 oncology trial reading out in the next 12 months — with a per-row staleness flag so you know which completion dates are still credible.
What oncology trials are reading out soon?
The "upcoming" section shows industry-sponsored Phase 3 oncology trials with primary completion ahead, soonest first, each graded by how credible that date is.
Which oncology trials have already read out?
The "recently read out" section shows Phase 3 oncology trials whose primary endpoint completed in the last 12 months — results posted, or completed and awaiting topline.
How are these readout dates sourced?
Every date is the ClinicalTrials.gov primary completion date — the only public, structured signal. We grade each by whether it is actual or sponsor-estimated, and by how recently the trial record was updated.
Where can I see readouts for other therapeutic areas?
The full cross-area calendar is on the main readout calendar; this page is the Oncology slice of it.
Recently read-out results are free; the upcoming calendar shows a free preview. See the full cross-area calendar → or the Oncology landscape →
Recently read out & awaiting topline — Oncology
· 22Phase 3 oncology trials whose primary endpoint completed in the last 12 months — results posted, or completed and awaiting topline. Most recent first.
| Sponsor | Trial / Asset | Indication | Status | Primary completion | Confidence | NCT |
|---|---|---|---|---|---|---|
| Arog Pharmaceuticals, Inc. | Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML Asset: Crenolanib | Newly Diagnosed FLT3 Mutated AML | Completed | Q2 2026 2026-04-06 | Completed · awaiting
Updated 7mo ago
| NCT03258931 |
| Arog Pharmaceuticals, Inc. | Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML Asset: Crenolanib | Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations | Completed | Q2 2026 2026-04-03 | Completed · awaiting
Updated 7mo ago
| NCT03250338 |
| Sandoz | A Study to Compare Efficacy, Safety, and Immunogenicity of GME751 and EU-authorized Keytruda in Adult Participants With Untreated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Asset: GME751 | Metastatic NSCLC | Completed | Q1 2026 2026-03-16 | Completed · awaiting
Updated 7mo ago
| NCT06159790 |
| Regeneron Pharmaceuticals | Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma Asset: Fianlimab | Melanoma | Active Not Recruiting | Q1 2026 2026-03-12 | Completed · awaiting
Updated 7mo ago
| NCT05352672 |
| Merck Sharp & Dohme LLC | A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84) | Lung Cancer +1 | Active Not Recruiting | Q1 2026 2026-03-12 | Completed · awaiting
Updated 7mo ago
| NCT06698042 |
| AstraZeneca | Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC Asset: Tremelimumab | Hepatocellular Carcinoma | Active Not Recruiting | Q1 2026 2026-02-23 | Completed · awaiting
Updated 7mo ago
| NCT05301842 |
| Karyopharm Therapeutics Inc | Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis Asset: Selinexor | Myelofibrosis | Active Not Recruiting | Q1 2026 2026-02-20 | Completed · awaiting
Updated 7mo ago
| NCT04562389 |
| Pfizer | Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC Asset: talazoparib plus enzalutamide | Prostate Cancer | Active Not Recruiting | Q1 2026 2026-02-18 | Completed · awaiting
Updated 7mo ago
| NCT04821622 |
| Bristol-Myers Squibb | A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer Asset: Nivolumab | Urinary Bladder Neoplasms +1 | Completed | Q1 2026 2026-02-16 | Completed · awaiting
Updated 7mo ago
| NCT03661320 |
| Boston Scientific Corporation | MANDARIN (S6371) | Inoperable Hepatocellular Carcinoma | Completed | Q1 2026 2026-02-13 | Completed · awaiting
Updated 7mo ago
| NCT05016245 |
| Merck Sharp & Dohme LLC | A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011) Asset: Belzutifan | Carcinoma, Renal Cell | Active Not Recruiting | Q1 2026 2026-02-02 | Completed · awaiting
Updated 8mo ago
| NCT04586231 |
| Hoffmann-La Roche | A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer) Asset: Giredestrant | Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer | Active Not Recruiting | Q1 2026 2026-01-30 | Completed · awaiting
Updated 9mo ago
| NCT04546009 |
| Dizal Pharmaceuticals | A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28) Asset: sunvozertinib | Non-small Cell Lung Cancer | Active Not Recruiting | Q1 2026 2026-01-16 | Completed · awaiting
Updated 9mo ago
| NCT05668988 |
| Merck Sharp & Dohme LLC | Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204) Asset: pembrolizumab | Hodgkin Lymphoma | Completed | Q1 2026 2026-01-14 | Completed · awaiting
Updated 9mo ago
| NCT02684292 |
| Seagen, a wholly owned subsidiary … | Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL Asset: Brentuximab vedotin | Diffuse Large B-cell Lymphoma | Active Not Recruiting | Q1 2026 2026-01-12 | Completed · awaiting
Updated 7mo ago
| NCT04404283 |
| Pfizer | A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma Asset: Encorafenib | Melanoma | Active Not Recruiting | Q1 2026 2026-01-12 | Completed · awaiting
Updated 7mo ago
| NCT04657991 |
| Eli Lilly and Company | A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) Asset: Selpercatinib | Carcinoma, Non-Small-Cell Lung | Active Not Recruiting | Q1 2026 2026-01-12 | Completed · awaiting
Updated 8mo ago
| NCT04819100 |
| Innovent Biologics (Suzhou) Co. Ltd. | A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC Asset: IBI310 | Hepatocellular Carcinoma | Completed | Q4 2025 2025-12-31 | Completed · awaiting
Updated 8mo ago
| NCT04720716 |
| Hoffmann-La Roche | A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer Asset: Atezolizumab | Non-Small Cell Lung Cancer | Active Not Recruiting | Q4 2025 2025-12-30 | Completed · awaiting
Updated 7mo ago
| NCT05047250 |
| Hoffmann-La Roche | A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer Asset: Atezolizumab | Non-Small Cell Lung Cancer | Completed | Q4 2025 2025-12-30 | Completed · awaiting
Updated 9mo ago
| NCT04294810 |
| Boehringer Ingelheim | Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma Asset: Brigimadlin | Liposarcoma, Dedifferentiated | Completed | Q4 2025 2025-12-12 | Completed · awaiting
Updated 10mo ago
| NCT06058793 |
| BeiGene | Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer Asset: Pamiparib capsule | Ovarian Cancer | Active Not Recruiting | Q4 2025 2025-12-01 | Completed · awaiting
Updated 8mo ago
| NCT03519230 |
Upcoming oncology readouts — next 12 months
· 218Industry Phase 3 oncology trials with primary completion ahead, soonest first — confidence-graded by date type and CT.gov staleness.
| Sponsor | Trial / Asset | Indication | Status | Primary completion | Confidence | NCT |
|---|---|---|---|---|---|---|
| Medicine Invention Design, Inc | Pharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms | ALK-Positive Non-Small Cell Lung Cancer (NSCLC) | Active Not Recruiting | Q4 2026 2026-11-18 (est.) | Estimated · aging
Updated 7mo ago
| NCT05987956 |
| Han Xu, M.D., Ph.D., FAPCR, Medica… | Pharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms Asset: ETOPOSIDE - Usual | Small Cell Lung Cancer | Active Not Recruiting | Q4 2026 2026-11-18 (est.) | Estimated · stale
Updated 16mo ago
| NCT01064466 |
| Tesaro, Inc. | A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer Asset: Dostarlimab | Neoplasms | Active Not Recruiting | Q4 2026 2026-11-26 (est.) | Estimated · stale
Updated 14mo ago
| NCT03981796 |
| Sichuan Kelun-Biotech Biopharmaceu… | A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Asset: SKB264 | Non-Small Cell Lung Cancer | Active Not Recruiting | Q4 2026 2026-11 (est.) | Estimated · aging
Updated 8mo ago
| NCT06448312 |
| InventisBio Co., Ltd | A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer Asset: D-0502 | Breast Cancer | Recruiting | Q4 2026 2026-11-30 (est.) | Estimated · aging
Updated 7mo ago
| NCT06954961 |
| Qilu Pharmaceutical Co., Ltd. | Efficacy and Safety Study of QLG1080 in Patients With Hormone-sensitive Advanced Prostate Cancer Asset: QLG1080 | Prostate Cancer | Completed | Q4 2026 2026-11 (est.) | Estimated · stale
Updated 21mo ago
| NCT06837896 |
| CAS Lamvac (Guangzhou) Biomedical … | Plasmodium Immunotherapy for Advanced Ovarian Cancer Asset: Plasmodium immunotherapy | Advanced Ovarian Cancer | Not Yet Recruiting | Q4 2026 2026-11-30 (est.) | Estimated · stale
Updated 28mo ago
| NCT05924776 |
| Janssen Research & Development, LLC | A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy Asset: Apalutamide | Prostatic Neoplasms | Active Not Recruiting | Q4 2026 2026-12-01 (est.) | Estimated · aging
Updated 7mo ago
| NCT03767244 |
| Shanghai Pharmaceuticals Holding C… | Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer Asset: SPH4336 Tablets | Locally Advanced or Metastatic Breast Cancer | Recruiting | Q4 2026 2026-12-01 (est.) | Estimated · aging
Updated 10mo ago
| NCT05860465 |
| Pfizer | A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer. Asset: PF-06821497 | Metastatic Castration-Resistant Prostate Cancer | Recruiting | Q4 2026 2026-12-02 (est.) | Estimated · aging
Updated 7mo ago
| NCT06629779 |
| CSPC Megalith Biopharmaceutical Co… | A Phase Ⅲ Clinical Study of SYS6010 in Combination With Osimertinib in Patients With Locally Advanced or Metastatic NSCLC Asset: SYS6010 | NSCLC | Not Yet Recruiting | Q4 2026 2026-12-12 (est.) | Estimated · aging
Updated 9mo ago
| NCT07376382 |
| Amgen | Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab) Asset: ABP 234 | Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC) | Active Not Recruiting | Q4 2026 2026-12-14 (est.) | Estimated · aging
Updated 7mo ago
| NCT06430866 |
| Shanghai JMT-Bio Inc. | A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer Asset: KN026 | Early or Locally Advanced HER2-positive Breast Cancer | Active Not Recruiting | Q4 2026 2026-12-16 (est.) | Estimated · stale
Updated 19mo ago
| NCT06747338 |
| Han Xu, M.D., Ph.D., FAPCR, Sponso… | Bioequivalence ANDA SNP Clinical Study - Raloxifene and Single Nucleotide Polymorphisms Asset: Raloxifene - Usual | Breast Cancer | Active Not Recruiting | Q4 2026 2026-12-18 (est.) | Estimated · aging
Updated 7mo ago
| NCT06062810 |
| Hoffmann-La Roche | A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC) Asset: Alectinib | Non-Small Cell Lung Cancer | Active Not Recruiting | Q4 2026 2026-12-20 (est.) | Estimated · aging
Updated 8mo ago
| NCT05170204 |
| Shanghai Kechow Pharma, Inc. | Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer Asset: Tunlametinib plus Vemurafenib | Colorectal Cancer Metastatic | Recruiting | Q4 2026 2026-12-24 (est.) | Estimated · stale
Updated 14mo ago
| NCT06008119 |
| Jiangsu Healthy Life Innovation Me… | Clinical Study of Tumor Treating Fields Combined with Gemcitabine and Albumin-bound Paclitaxel in the First-line Treatment of Locally Advanced Pancreatic Cancer | Locally Advanced Pancreatic Cancer | Recruiting | Q4 2026 2026-12-25 (est.) | Estimated · stale
Updated 20mo ago
| NCT05653453 |
| CanariaBio Inc. | Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery Asset: Oregovomab | Carcinoma, Ovarian Epithelial +9 | Active Not Recruiting | Q4 2026 2026-12-26 (est.) | Estimated · aging
Updated 7mo ago
| NCT04498117 |
| Janssen Research & Development, LLC | A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder Asset: Cetrelimab | Urinary Bladder Neoplasms | Active Not Recruiting | Q4 2026 2026-12-30 (est.) | Estimated · aging
Updated 7mo ago
| NCT04658862 |
| Pfizer | Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer | Breast Cancer | Active Not Recruiting | Q4 2026 2026-12-30 (est.) | Estimated · aging
Updated 9mo ago
| NCT05909397 |
| AskGene Pharma, Inc. | ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ Adenocarcinoma Asset: ASKB589 | Gastroesophageal Junction Adenocarcinoma +1 | Active Not Recruiting | Q4 2026 2026-12-30 (est.) | Estimated · aging
Updated 10mo ago
| NCT06206733 |
| Xynomic Pharmaceuticals, Inc. | A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV) Asset: Pazopanib | Renal Cell Carcinoma | Recruiting | Q4 2026 2026-12-30 (est.) | Estimated · stale
Updated 19mo ago
| NCT03592472 |
| Jiangsu vcare pharmaceutical techn… | Phase III Clinical Study of VC004 in Patients With Localized Advanced/ Metastatic Solid Tumors Asset: VC004 Capsules | Locally Advanced Solid Tumor | Recruiting | Q4 2026 2026-12-30 (est.) | Estimated · stale
Updated 20mo ago
| NCT06658353 |
| Jiangsu Alphamab Biopharmaceutical… | JSKN003 in Platinum-Resistant, Relapsed Epithelial Ovarian Cancer Asset: JSKN003 | Ovarian Cancer +2 | Not Yet Recruiting | Q4 2026 2026-12-30 (est.) | Estimated · stale
Updated 22mo ago
| NCT06751485 |
| Beijing Konruns Pharmaceutical Co.… | A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer Asset: KC1036 | Esophageal Squamous Cell Carcinoma | Recruiting | Q4 2026 2026-12-30 (est.) | Estimated · stale
Updated 32mo ago
| NCT06194734 |
| Hoffmann-La Roche | A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial Asset: Pertuzumab | Solid Tumors | Active Not Recruiting | Q4 2026 2026-12-31 (est.) | Estimated · aging
Updated 9mo ago
| NCT02320435 |
| Janssen Research & Development, LLC | A Long-term Extension Study of PCI-32765 (Ibrutinib) Asset: Ibrutinib | Chronic Lymphocytic Leukemia +6 | Active Not Recruiting | Q4 2026 2026-12-31 (est.) | Estimated · aging
Updated 7mo ago
| NCT01804686 |
| Hoffmann-La Roche | A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer Asset: Inavolisib | Metastatic Breast Cancer | Recruiting | Q4 2026 2026-12-31 (est.) | Estimated · aging
Updated 7mo ago
| NCT05894239 |
| Swedish Orphan Biovitrum | A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis Asset: Pacritinib | Primary Myelofibrosis +2 | Active Not Recruiting | Q4 2026 2026-12-31 (est.) | Estimated · aging
Updated 9mo ago
| NCT03165734 |
| AstraZeneca | Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab Asset: Durvalumab | Cancer | Enrolling By Invitation | Q4 2026 2026-12-31 (est.) | Estimated · aging
Updated 7mo ago
| NCT05303532 |
| Jiangsu HengRui Medicine Co., Ltd. | An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors. Asset: Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide | Advanced Gastroenteropancreatic Neuroendocrine Tumor | Recruiting | Q4 2026 2026-12 (est.) | Estimated · aging
Updated 7mo ago
| NCT05884255 |
| Chia Tai Tianqing Pharmaceutical G… | Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer Asset: TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen | Breast Cancer | Active Not Recruiting | Q4 2026 2026-12 (est.) | Estimated · aging
Updated 7mo ago
| NCT05780567 |
| Sichuan Baili Pharmaceutical Co., … | A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer(PANKU-Lung02) Asset: BL-B01D1 | Non-small Cell Lung Cancer | Active Not Recruiting | Q4 2026 2026-12 (est.) | Estimated · aging
Updated 7mo ago
| NCT06382129 |
| Sichuan Baili Pharmaceutical Co., … | A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer(PANKU-Lung03) Asset: BL-B01D1 | Small Cell Lung Cancer | Active Not Recruiting | Q4 2026 2026-12 (est.) | Estimated · aging
Updated 7mo ago
| NCT06500026 |
| NaviFUS Corporation | A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients Asset: Bevacizumab | Glioblastoma Multiforme +7 | Recruiting | Q4 2026 2026-12-31 (est.) | Estimated · aging
Updated 7mo ago
| NCT06496971 |
| Clarity Pharmaceuticals Ltd | 64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer Asset: 64Cu-SAR-bisPSMA | Prostate Cancer +5 | Active Not Recruiting | Q4 2026 2026-12-31 (est.) | Estimated · aging
Updated 7mo ago
| NCT06970847 |
| RayzeBio, Inc. | Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy Asset: RYZ101 | GEP-NET +6 | Active Not Recruiting | Q4 2026 2026-12 (est.) | Estimated · aging
Updated 7mo ago
| NCT05477576 |
| Vergent Bioscience, Inc. | Evaluation of the Safety and Efficacy of Abenacianine (VGT-309) to Identify Cancer in Subjects Undergoing Surgery for Cancer in the Lung Asset: Abenacianine | Lung Cancer +1 | Recruiting | Q4 2026 2026-12 (est.) | Estimated · aging
Updated 7mo ago
| NCT07499674 |
| Greenwich LifeSciences, Inc. | Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects Asset: Placebo | Breast Cancer | Recruiting | Q4 2026 2026-12 (est.) | Estimated · aging
Updated 8mo ago
| NCT05232916 |
| Suzhou Suncadia Biopharmaceuticals… | A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC Asset: SHR-A2009 monotherapy | Non-small Cell Lung Cancer | Active Not Recruiting | Q4 2026 2026-12 (est.) | Estimated · aging
Updated 8mo ago
| NCT06671379 |
| Akeso | AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer Asset: AK112 | Triple-Negative Breast Cancer (TNBC) | Recruiting | Q4 2026 2026-12 (est.) | Estimated · aging
Updated 8mo ago
| NCT06767527 |
| Aldeyra Therapeutics, Inc. | A Clinical Trial Evaluating Patients With Primary Vitreoretinal Lymphoma Asset: ICM ADX-2191 injection | Primary Vitreoretinal Lymphoma | Recruiting | Q4 2026 2026-12 (est.) | Estimated · aging
Updated 9mo ago
| NCT07402876 |
| Gilead Sciences | Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC) Asset: Sacituzumab Govitecan-hziy | Metastatic Breast Cancer | Active Not Recruiting | Q4 2026 2026-12 (est.) | Estimated · aging
Updated 9mo ago
| NCT04639986 |
| Sichuan Kelun-Biotech Biopharmaceu… | A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Asset: SKB264 | Non-Small Cell Lung Cancer | Active Not Recruiting | Q4 2026 2026-12 (est.) | Estimated · aging
Updated 9mo ago
| NCT06711900 |
| Shandong Suncadia Medicine Co., Ltd. | A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer Asset: HRS-8080 Tablet | Locally Advanced Breast Cancer +1 | Recruiting | Q4 2026 2026-12 (est.) | Estimated · aging
Updated 10mo ago
| NCT07024173 |
| Guangzhou Gloria Biosciences Co., … | Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients Asset: Motixafortide+G-CSF | Multiple Myeloma | Recruiting | Q4 2026 2026-12-31 (est.) | Estimated · aging
Updated 11mo ago
| NCT06514508 |
| Kartos Therapeutics, Inc. | Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib Asset: Navtemadlin | Myelofibrosis +4 | Recruiting | Q4 2026 2026-12-31 (est.) | Estimated · stale
Updated 14mo ago
| NCT06479135 |
| Qilu Pharmaceutical Co., Ltd. | Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC) Asset: QL2107 | Carcinoma, Non-Small-Cell Lung | Active Not Recruiting | Q4 2026 2026-12-31 (est.) | Estimated · stale
Updated 14mo ago
| NCT07162883 |
| Jiangsu HengRui Medicine Co., Ltd. | A Trial of SHR-A1811versus Pyrotinib in Combination With Capecitabine in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane Asset: SHR-A1811 | HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane | Active Not Recruiting | Q4 2026 2026-12-31 (est.) | Estimated · stale
Updated 15mo ago
| NCT05424835 |
| TVAX Biomedical | Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM) Asset: TVI-Brain-1 | Glioblastoma Multiforme of Brain | Active Not Recruiting | Q4 2026 2026-12 (est.) | Estimated · stale
Updated 16mo ago
| NCT05685004 |
| Qilu Pharmaceutical Co., Ltd. | A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC Asset: QL2107 | NSCLC | Recruiting | Q4 2026 2026-12 (est.) | Estimated · stale
Updated 17mo ago
| NCT06754644 |
| Changchun GeneScience Pharmaceutic… | Nano-crystalline Megestrol Acetate Combined With Standard Treatment Versus Standard Treatment for First-line Extensive-stage Small Cell Lung Cancer in the Cachexia Phase Asset: Nano-crystalline Megestrol Acetate Oral Suspension | Extensive-stage Small Cell Lung Cancer (ES-SCLC) +1 | Not Yet Recruiting | Q4 2026 2026-12-31 (est.) | Estimated · stale
Updated 18mo ago
| NCT06961201 |
| Chia Tai Tianqing Pharmaceutical G… | A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC) Asset: AK105 Injection | Advanced Hepatocellular Carcinoma (HCC) | Active Not Recruiting | Q4 2026 2026-12 (est.) | Estimated · stale
Updated 21mo ago
| NCT04344158 |
| Jiangsu HengRui Medicine Co., Ltd. | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer Asset: Fuzuloparib , Abiraterone acetate and Prednisone | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Active Not Recruiting | Q4 2026 2026-12-31 (est.) | Estimated · stale
Updated 22mo ago
| NCT04691804 |
| Mabscale, LLC | A Safety and Efficacy Study of Bevacizumab, Paclitaxel, Carboplatin Compared to Avastin® in Non-Small Cell Lung Cancer Asset: Bevacizumab | Non-Small Cell Lung Cancer | Recruiting | Q4 2026 2026-12 (est.) | Estimated · stale
Updated 27mo ago
| NCT05654454 |
| RemeGen Co., Ltd. | DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy Asset: Disitamab Vedotin Injection | Gastric Cancer +1 | Recruiting | Q4 2026 2026-12 (est.) | Estimated · stale
Updated 31mo ago
| NCT06221748 |
| RemeGen Co., Ltd. | A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma Asset: RC48-ADC | Urothelial Carcinoma +1 | Recruiting | Q4 2026 2026-12-31 (est.) | Estimated · stale
Updated 35mo ago
| NCT05302284 |
| GC Cell Corporation | Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer Asset: Immuncell-LC | Pancreatic Ductal Adenocarcinoma | Recruiting | Q4 2026 2026-12 (est.) | Estimated · stale
Updated 60mo ago
| NCT04969731 |
| Merck Sharp & Dohme LLC | A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015) Asset: Sacituzumab tirumotecan | Gastroesophageal Cancer | Active Not Recruiting | Q1 2027 2027-01-04 (est.) | Estimated · aging
Updated 9mo ago
| NCT06356311 |
| Celgene | A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) Asset: mezigdomide | Relapsed or Refractory Multiple Myeloma | Recruiting | Q1 2027 2027-01-10 (est.) | Estimated · aging
Updated 8mo ago
| NCT05519085 |
| FutureGen Biopharmaceutical (Beiji… | M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma. Asset: M108 monoclonal antibody | Locally Advanced Unresectable or Metastatic Gastric Cancer +1 | Recruiting | Q1 2027 2027-01-11 (est.) | Estimated · stale
Updated 32mo ago
| NCT06177041 |
| Merck Sharp & Dohme LLC | Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46) Asset: Sacituzumab Govitecan | Carcinoma, Non-Small-Cell Lung | Active Not Recruiting | Q1 2027 2027-01-12 (est.) | Estimated · aging
Updated 11mo ago
| NCT05609968 |
| IDEAYA Biosciences | IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma Asset: IDE196 | Metastatic Uveal Melanoma | Active Not Recruiting | Q1 2027 2027-01-15 (est.) | Estimated · aging
Updated 9mo ago
| NCT05987332 |
| Biotheus Inc. | PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer Asset: PM8002 | SCLC | Active Not Recruiting | Q1 2027 2027-01-25 (est.) | Estimated · stale
Updated 23mo ago
| NCT06616532 |
| Novartis Pharmaceuticals | Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor. Asset: Alpelisib | Breast Cancer | Active Not Recruiting | Q1 2027 2027-01-28 (est.) | Estimated · aging
Updated 7mo ago
| NCT05038735 |
| Shanghai Runshi Pharmaceutical Tec… | A Study of Simmitinib Versus Chemotherapy for Participants With Advanced Oesophageal Squamous Cell Carcinoma Asset: simmitinib | Advanced Oesophageal Squamous Cell Carcinoma | Not Yet Recruiting | Q1 2027 2027-01-30 (est.) | Estimated · stale
Updated 25mo ago
| NCT06656091 |
| Merck Sharp & Dohme LLC | Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992) Asset: Pembrolizumab | Urinary Bladder Neoplasms | Active Not Recruiting | Q1 2027 2027-01-31 (est.) | Estimated · stale
Updated 24mo ago
| NCT04241185 |
| Resilience | Randomized Controlled Trial of Remote Symptoms Monitoring With Resilience PRO Compared to Care As Usual Only | Cancer | Recruiting | Q1 2027 2027-01 (est.) | Estimated · aging
Updated 7mo ago
| NCT06867705 |
| Chia Tai Tianqing Pharmaceutical G… | A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma Asset: AL2846 Capsules | Thyroid Cancer | Recruiting | Q1 2027 2027-01 (est.) | Estimated · aging
Updated 10mo ago
| NCT06860971 |
| NX Development Corp | Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302) Asset: Gleolan | Ovarian Cancer | Recruiting | Q1 2027 2027-01 (est.) | Estimated · stale
Updated 13mo ago
| NCT05804370 |
| Biocad | A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma Asset: BCD-217 | Melanoma Stage III +1 | Active Not Recruiting | Q1 2027 2027-01 (est.) | Estimated · stale
Updated 16mo ago
| NCT05751928 |
| Loxo Oncology, Inc. | Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) Asset: Pirtobrutinib | Lymphoma, Mantle-Cell | Active Not Recruiting | Q1 2027 2027-01 (est.) | Estimated · stale
Updated 18mo ago
| NCT04662255 |
| Acerta Pharma BV | Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL Asset: Acalabrutinib | Chronic Lymphocytic Leukemia | Active Not Recruiting | Q1 2027 2027-01-31 (est.) | Estimated · stale
Updated 23mo ago
| NCT03836261 |
| Akeso | A Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) Asset: AK117 in combination with AK112 | Head and Neck Squamous Cell Carcinoma | Recruiting | Q1 2027 2027-01 (est.) | Estimated · stale
Updated 24mo ago
| NCT06601335 |
| Chia Tai Tianqing Pharmaceutical G… | A Clinical Trial of TQB2102 for Injection in the Treatment of HER2 Low-Expressing Recurrent/Metastatic Breast Cancer Asset: TQB2102 for Injection | Breast Cancer | Active Not Recruiting | Q1 2027 2027-01 (est.) | Estimated · stale
Updated 27mo ago
| NCT06561607 |
| Merck Sharp & Dohme LLC | Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975) Asset: pembrolizumab | Esophageal Squamous Cell Carcinoma (ESCC) +2 | Completed | Q1 2027 2027-02-01 (est.) | Estimated · stale
Updated 24mo ago
| NCT04210115 |
| GlaxoSmithKline | A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC) Asset: Dostarlimab | Lung Cancer, Non-Small Cell | Active Not Recruiting | Q1 2027 2027-02-02 (est.) | Estimated · stale
Updated 14mo ago
| NCT06472076 |
| Epizyme, Inc. | A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma. Asset: Tazemetostat | Relapsed/Refractory Follicular Lymphoma +2 | Active Not Recruiting | Q1 2027 2027-02-13 (est.) | Estimated · aging
Updated 7mo ago
| NCT04224493 |
| Acerta Pharma BV | A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL Asset: Acalabrutinib | Lymphoma, Mantle Cell | Active Not Recruiting | Q1 2027 2027-02-15 (est.) | Estimated · aging
Updated 9mo ago
| NCT02972840 |
| Hoffmann-La Roche | A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer) Asset: Giredestrant | Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer | Active Not Recruiting | Q1 2027 2027-02-19 (est.) | Estimated · aging
Updated 7mo ago
| NCT06065748 |
| AstraZeneca | Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib (TAGRISSO) (ROSY-T) Asset: Osimertinib | Cancer | Active Not Recruiting | Q1 2027 2027-02-22 (est.) | Estimated · aging
Updated 7mo ago
| NCT05629234 |
| Acerta Pharma BV | A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) Asset: acalabrutinib | Diffuse Large B-Cell Lymphoma | Active Not Recruiting | Q1 2027 2027-02-22 (est.) | Estimated · aging
Updated 7mo ago
| NCT04529772 |
| Novartis Pharmaceuticals | Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation Asset: Alpelisib | Advanced HER2+Breast Cancer | Active Not Recruiting | Q1 2027 2027-02-26 (est.) | Estimated · aging
Updated 7mo ago
| NCT04208178 |
| Genmab | Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer Asset: Rina-S | Platinum-resistant Ovarian Cancer | Active Not Recruiting | Q1 2027 2027-02 (est.) | Estimated · aging
Updated 8mo ago
| NCT06619236 |
| Gilead Sciences | Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer Asset: Sacituzumab Govitecan-hziy | Triple Negative Breast Cancer +1 | Active Not Recruiting | Q1 2027 2027-02 (est.) | Estimated · stale
Updated 14mo ago
| NCT05382286 |
| Celltrion | A Study to Compare Effects and Safety of CT-P51 and Keytruda in Patients With Previously Untreated Metastatic Lung Cancer Asset: CT-P51 | Non Squamous Non Small Cell Lung Cancer | Active Not Recruiting | Q1 2027 2027-02 (est.) | Estimated · stale
Updated 19mo ago
| NCT06939595 |
| Hansoh BioMedical R&D Company | HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer Asset: HS-20089 | Ovarian Cancer | Recruiting | Q1 2027 2027-03-07 (est.) | Estimated · aging
Updated 11mo ago
| NCT06855069 |
| Bristol-Myers Squibb | A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer Asset: Nivolumab | Renal Cell Carcinoma | Active Not Recruiting | Q1 2027 2027-03-11 (est.) | Estimated · aging
Updated 10mo ago
| NCT03873402 |
| Regeneron Pharmaceuticals | A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head) Asset: fianlimab | Melanoma | Recruiting | Q1 2027 2027-03-22 (est.) | Estimated · aging
Updated 9mo ago
| NCT06246916 |
| Shanghai JMT-Bio Inc. | JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations Asset: JMT101 Injection | Local Advanced or Metastatic NSCLC | Not Yet Recruiting | Q1 2027 2027-03-26 (est.) | Estimated · stale
Updated 31mo ago
| NCT06380348 |
| Jiangsu HengRui Medicine Co., Ltd. | A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer Asset: Rezvilutamide Tablets | Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | Recruiting | Q1 2027 2027-03 (est.) | Estimated · aging
Updated 9mo ago
| NCT07241416 |
| Novartis Pharmaceuticals | Study of Out of Specification for Tisagenlecleucel Asset: CTL019 | B-cell Acute Lymphoblastic Leukemia +1 | Recruiting | Q1 2027 2027-03-31 (est.) | Estimated · aging
Updated 7mo ago
| NCT04094311 |
| TuHURA Biosciences, Inc. | Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma Asset: IFx-Hu2.0 | Advanced Or Metastatic Merkel Cell Carcinoma | Recruiting | Q1 2027 2027-03-31 (est.) | Estimated · aging
Updated 7mo ago
| NCT06947928 |
| Hoffmann-La Roche | A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy Asset: Tiragolumab | Esophageal Squamous Cell Carcinoma | Completed | Q1 2027 2027-03-31 (est.) | Estimated · aging
Updated 7mo ago
| NCT04543617 |
| Quetzal Therapeutics | Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia Asset: QTX-2101 + ATRA | Acute Promyelocytic Leukemia (APL) +4 | Recruiting | Q1 2027 2027-03 (est.) | Estimated · aging
Updated 7mo ago
| NCT07504458 |
| ABX advanced biochemical compounds… | Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer Asset: [18F]PSMA-1007 | Prostate Cancer | Recruiting | Q1 2027 2027-03 (est.) | Estimated · aging
Updated 7mo ago
| NCT06122584 |
| Suzhou Suncadia Biopharmaceuticals… | A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma Asset: SHR-A1912 Injection | Diffuse Large B-cell Lymphoma | Active Not Recruiting | Q1 2027 2027-03 (est.) | Estimated · aging
Updated 12mo ago
| NCT06929624 |
| BeOne Medicines | A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation Asset: zanubrutinib | Mantle Cell Lymphoma; Non-Hodgkin Lymphoma | Active Not Recruiting | Q1 2027 2027-03 (est.) | Estimated · stale
Updated 14mo ago
| NCT04002297 |
| Hangzhou Sumgen Biotech Co., Ltd. | A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients Asset: SG301 Injection | Relapsed/Refractory Multiple Myeloma | Recruiting | Q1 2027 2027-03-31 (est.) | Estimated · stale
Updated 17mo ago
| NCT06508983 |
| Seattle Project Corporation | A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer Asset: GRT-C901 | Colorectal Neoplasms | Active Not Recruiting | Q1 2027 2027-03 (est.) | Estimated · stale
Updated 18mo ago
| NCT05141721 |
| Pierre Fabre Medicament | Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation. Asset: Encorafenib and Binimetinib | Melanoma | Active Not Recruiting | Q1 2027 2027-03-31 (est.) | Estimated · stale
Updated 36mo ago
| NCT05270044 |
| Jiangsu Famous Medical Technology … | Xian-Lian-Jie-Du Optimization Decoction As an Adjuvant Treatment for Prevention of Recurrence of Colon Cancer Asset: XLJDOD compound granule | Colon Cancer | Recruiting | Q2 2027 2027-04-01 (est.) | Estimated · stale
Updated 22mo ago
| NCT05709249 |
| AstraZeneca | Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib Asset: Olaparib | Ovarian Cancer +1 | Active Not Recruiting | Q2 2027 2027-04-06 (est.) | Estimated · aging
Updated 7mo ago
| NCT04421963 |
| Celgene | Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) Asset: bb2121 | Multiple Myeloma | Completed | Q2 2027 2027-04-08 (est.) | Estimated · stale
Updated 47mo ago
| NCT03651128 |
| Shanghai Henlius Biotech | A Study to Compare the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profile of HLX17 Vs. Keytruda® in the First-Line Treatment of Advanced Non-squamous Non-small Cell Lung Cancer Asset: HLX17 | Non-Squamous Non-Small Cell Lung Cancer | Not Yet Recruiting | Q2 2027 2027-04-09 (est.) | Estimated · stale
Updated 21mo ago
| NCT06847334 |
| AstraZeneca | A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy Asset: Camizestrant | Breast Cancer, Early Breast Cancer | Recruiting | Q2 2027 2027-04-20 (est.) | Estimated · aging
Updated 7mo ago
| NCT05774951 |
| LeonaBio | Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation Asset: Lasofoxifene in combination with abemaciclib | Metastatic Breast Cancer | Recruiting | Q2 2027 2027-04 (est.) | Estimated · aging
Updated 7mo ago
| NCT05696626 |
| Taiho Oncology, Inc. | Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy. Asset: futibatinib | Advanced/Metastatic Cancer | Active Not Recruiting | Q2 2027 2027-04 (est.) | Estimated · aging
Updated 7mo ago
| NCT06506955 |
| Daiichi Sankyo | A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer Asset: Ifinatamab deruxtecan | Small Cell Lung Cancer | Recruiting | Q2 2027 2027-04-30 (est.) | Estimated · aging
Updated 8mo ago
| NCT06203210 |
| AbbVie | Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Asset: Mirvetuximab soravtansine plus Bevacizumab | Ovarian Cancer +2 | Active Not Recruiting | Q2 2027 2027-04 (est.) | Estimated · aging
Updated 9mo ago
| NCT05445778 |
| mAbxience Research S.L. | Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] Melanoma Asset: MB11 (Proposed Nivolumab Biosimilar) | Advanced (Unresectable or Metastatic) Melanoma | Recruiting | Q2 2027 2027-04 (est.) | Estimated · aging
Updated 10mo ago
| NCT07221734 |
| Shanghai Fosun Pharmaceutical Indu… | FCN-159 Monotherapy Versus Chemotherapy by Investigator's Choice in Pediatric Low-grade Glioma Patients With BRAF Alteration Asset: Luvometinib | Low-grade Glioma +2 | Not Yet Recruiting | Q2 2027 2027-04-30 (est.) | Estimated · stale
Updated 17mo ago
| NCT07004075 |
| Merck Sharp & Dohme LLC | Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004) Asset: Sacituzumab tirumotecan | Non-small Cell Lung Cancer (NSCLC) | Active Not Recruiting | Q2 2027 2027-05-10 (est.) | Estimated · aging
Updated 7mo ago
| NCT06074588 |
| Regeneron Pharmaceuticals | A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma Asset: Odronextamab | B-Cell Non-Hodgkin Lymphoma (B-NHL) | Active Not Recruiting | Q2 2027 2027-05-14 (est.) | Estimated · aging
Updated 7mo ago
| NCT06230224 |
| Akeso | A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer Asset: Ivonescimab, AK117, Albumin-bound Paclitaxel, Gemcitabine | Pancreatic Cancer | Recruiting | Q2 2027 2027-05-14 (est.) | Estimated · aging
Updated 8mo ago
| NCT06953999 |
| Merck Sharp & Dohme LLC | A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008) Asset: Nemtabrutinib | Chronic Lymphocytic Leukemia +1 | Active Not Recruiting | Q2 2027 2027-05-19 (est.) | Estimated · aging
Updated 8mo ago
| NCT05624554 |
| Merck Sharp & Dohme LLC | Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15) Asset: pembrolizumab | Endometrial Neoplasms | Active Not Recruiting | Q2 2027 2027-05-27 (est.) | Estimated · stale
Updated 24mo ago
| NCT05173987 |
| Sichuan Kelun-Biotech Biopharmaceu… | A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Asset: SKB264 | Non-Small Cell Lung Cancer | Active Not Recruiting | Q2 2027 2027-05 (est.) | Estimated · aging
Updated 11mo ago
| NCT06670196 |
| Priothera SAS | Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT Asset: mocravimod | Adult Acute Myeloid Leukemia | Recruiting | Q2 2027 2027-05 (est.) | Estimated · aging
Updated 7mo ago
| NCT05429632 |
| Jiangsu HengRui Medicine Co., Ltd. | A Study of SHR-A1811 in Subjects With Ovarian Cancer Asset: SHR-A1811 | Ovarian Cancer | Recruiting | Q2 2027 2027-05 (est.) | Estimated · aging
Updated 7mo ago
| NCT06828354 |
| Akeso | Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer Asset: Ivonescimab, docetaxel | Non-Small Cell Lung Cancer | Recruiting | Q2 2027 2027-05 (est.) | Estimated · aging
Updated 7mo ago
| NCT06928389 |
| Sichuan Baili Pharmaceutical Co., … | A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer Asset: BL-M07D1 | HER2-low Breast Cancer | Recruiting | Q2 2027 2027-05 (est.) | Estimated · aging
Updated 10mo ago
| NCT06957886 |
| Suzhou Immunofoco Biotechnology Co… | A Phase III Randomized Study in CLDN18.2-positive Unresectable Locally Advanced Gastric Cancer Patients Asset: CAR T cells | Gastric Adenocarcinoma | Recruiting | Q2 2027 2027-05-31 (est.) | Estimated · stale
Updated 13mo ago
| NCT07103668 |
| Qilu Pharmaceutical Co., Ltd. | A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer Asset: MHB088C for Injection | Small Cell Lung Cancer Extensive Stage | Recruiting | Q2 2027 2027-05 (est.) | Estimated · stale
Updated 17mo ago
| NCT06954246 |
| InSightec | Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets Asset: Pembrolizumab | Brain Tumor +1 | Recruiting | Q2 2027 2027-06-01 (est.) | Estimated · aging
Updated 7mo ago
| NCT05317858 |
| Shanghai Henlius Biotech | A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer Asset: HLX22 | Gastroesophageal-junction Cancer +3 | Recruiting | Q2 2027 2027-06-01 (est.) | Estimated · aging
Updated 9mo ago
| NCT06532006 |
| Shanghai JMT-Bio Inc. | The Study of JMT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Colorectal Cancer Asset: JMT101 | Metastatic Colorectal Cancer (mCRC) | Not Yet Recruiting | Q2 2027 2027-06-01 (est.) | Estimated · stale
Updated 15mo ago
| NCT07134205 |
| Novartis Pharmaceuticals | An Extension Study for Patients Previously Enrolled in Studies With Pelabresib Asset: Pelabresib | Hematologic Malignancy +2 | Recruiting | Q2 2027 2027-06-02 (est.) | Estimated · stale
Updated 17mo ago
| NCT06401356 |
| Shanghai Henlius Biotech | A Study to Compare the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profile of HLX13 with YERVOY As a First-Line Treatment for Patients with Unresectable Hepatocellular Carcinoma Asset: HLX13 | Hepatocellular Carcinoma (HCC) | Not Yet Recruiting | Q2 2027 2027-06-06 (est.) | Estimated · stale
Updated 21mo ago
| NCT06841185 |
| Merck Sharp & Dohme LLC | A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study Asset: Pembrolizumab | Carcinoma, Renal Cell | Active Not Recruiting | Q2 2027 2027-06-07 (est.) | Estimated · aging
Updated 12mo ago
| NCT05899049 |
| Bristol-Myers Squibb | ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions Asset: Luspatercept | Myelodysplastic Syndromes | Active Not Recruiting | Q2 2027 2027-06-25 (est.) | Estimated · aging
Updated 8mo ago
| NCT05949684 |
| Amgen | A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) Asset: Sotorasib | Non-Small Cell Lung Cancer (NSCLC) | Recruiting | Q2 2027 2027-06-30 (est.) | Estimated · aging
Updated 7mo ago
| NCT05920356 |
| Gilead Sciences | Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63) Asset: Sacituzumab govitecan-hziy (SG) | Triple Negative Breast Cancer | Recruiting | Q2 2027 2027-06 (est.) | Estimated · aging
Updated 10mo ago
| NCT05633654 |
| BeiGene | Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma Asset: Tislelizumab | Urothelial Carcinoma | Active Not Recruiting | Q2 2027 2027-06-30 (est.) | Estimated · aging
Updated 7mo ago
| NCT03967977 |
| Sichuan Baili Pharmaceutical Co., … | A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Urothelial Carcinoma(PANKU-Bladder01) Asset: BL-B01D1 | Urothelial Carcinoma | Active Not Recruiting | Q2 2027 2027-06 (est.) | Estimated · aging
Updated 7mo ago
| NCT06857175 |
| Sichuan Baili Pharmaceutical Co., … | A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01) Asset: BL-B01D1 | Epithelial Ovarian Cancer +2 | Recruiting | Q2 2027 2027-06 (est.) | Estimated · aging
Updated 7mo ago
| NCT06994195 |
| Hoffmann-La Roche | An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C) Asset: Atezolizumab | Neoplasms | Active Not Recruiting | Q2 2027 2027-06-30 (est.) | Estimated · aging
Updated 7mo ago
| NCT05112965 |
| Immutep S.A.S. | Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004) Asset: eftilagimod alfa | Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | Active Not Recruiting | Q2 2027 2027-06 (est.) | Estimated · aging
Updated 8mo ago
| NCT06726265 |
| Pharmacosmos A/S | Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer Asset: Trilaciclib | Limited Stage Small Cell Lung Cancer | Recruiting | Q2 2027 2027-06 (est.) | Estimated · aging
Updated 8mo ago
| NCT07473128 |
| Day One Biopharmaceuticals, Inc. | DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2) Asset: Tovorafenib | Low-grade Glioma +2 | Active Not Recruiting | Q2 2027 2027-06 (est.) | Estimated · aging
Updated 8mo ago
| NCT05566795 |
| AstraZeneca | A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features Asset: Datopotamab Deruxtecan | Non-small Cell Lung Cancer | Active Not Recruiting | Q2 2027 2027-06-30 (est.) | Estimated · aging
Updated 10mo ago
| NCT06564844 |
| Changchun GeneScience Pharmaceutic… | Nanocrystalline Megestrol Acetate for Cachectic Stage Locally Advanced Hepatocellular Carcinoma Asset: Nanocrystalline Megestrol Acetate | Cachexia +1 | Not Yet Recruiting | Q2 2027 2027-06-30 (est.) | Estimated · aging
Updated 10mo ago
| NCT07356037 |
| SDK Therapeutics, Inc. | A Trial to Investigate Whether Oral Arsenic Trioxide Is Similar to Intravenous Arsenic Trioxide in Pharmacokinetics, Safety, and Efficacy (LATITUDE/SDKARS-301) Asset: Oral ATO | Acute Promyelocytic Leukemia (APL) +8 | Not Yet Recruiting | Q2 2027 2027-06 (est.) | Estimated · aging
Updated 10mo ago
| NCT07296445 |
| Genfleet Therapeutics (Shanghai) I… | Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer Asset: GFH375 | Metastatic Pancreatic Cancer | Recruiting | Q2 2027 2027-06 (est.) | Estimated · aging
Updated 11mo ago
| NCT07262567 |
| Sichuan Baili Pharmaceutical Co., … | A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-positive Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction Adenocarcinoma Asset: BL-M07D1 | Gastric Adenocarcinoma +1 | Recruiting | Q2 2027 2027-06 (est.) | Estimated · aging
Updated 12mo ago
| NCT07152405 |
| Qilu Pharmaceutical Co., Ltd. | A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer Asset: ESG401 | Triple-Negative Breast Cancer (TNBC) | Recruiting | Q2 2027 2027-06 (est.) | Estimated · stale
Updated 14mo ago
| NCT06732323 |
| ITM Solucin GmbH | Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE Asset: 177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT | Neuroendocrine Tumors | Active Not Recruiting | Q2 2027 2027-06 (est.) | Estimated · stale
Updated 14mo ago
| NCT04919226 |
| Changchun GeneScience Pharmaceutic… | Nanocrystalline Megestrol Acetate in Concurrent Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer Asset: Nano-crystalline Megestrol Acetate Oral Suspension | Non-small Cell Lung Cancer | Recruiting | Q2 2027 2027-06-30 (est.) | Estimated · stale
Updated 14mo ago
| NCT07150663 |
| Lepu Biopharma Co., Ltd. | A Study Comparing MRG004A Plus Best Supportive Care Versus Placebo and Best Supportive Care in the Treatment of Patients With Advanced Pancreatic Cancer Asset: MRG004A plus best supportive care | Advanced Pancreatic Cancer | Not Yet Recruiting | Q2 2027 2027-06 (est.) | Estimated · stale
Updated 15mo ago
| NCT07138846 |
| Innovent Biologics (Suzhou) Co. Ltd. | A Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Pancreatic Cancer(G-HOPE-002) Asset: IBI343 | Pancreatic Cancer | Recruiting | Q2 2027 2027-06-30 (est.) | Estimated · stale
Updated 15mo ago
| NCT07066098 |
| Qilu Pharmaceutical Co., Ltd. | A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer Asset: ESG401 | Metastatic Breast Cancer | Recruiting | Q2 2027 2027-06-30 (est.) | Estimated · stale
Updated 17mo ago
| NCT06383767 |
| Changchun GeneScience Pharmaceutic… | Clinical Study on Nanocrystalline Megestrol Acetate for Appetite Improvement and Weight Gain in Pre-Cachexia and Cachexia Stages Key Terminology Analysis Asset: Nano-crystalline Megestrol Acetate Oral Suspension | Metastatic (Stage IV) Non-squamous Non-small Cell Lung Cancer (Nsq-NSCLC) With Driver Gene Negativity +1 | Not Yet Recruiting | Q2 2027 2027-06-30 (est.) | Estimated · stale
Updated 18mo ago
| NCT06961188 |
| Genmab | A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) Asset: Epcoritamab | Diffuse Large B-Cell Lymphoma | Active Not Recruiting | Q2 2027 2027-06 (est.) | Estimated · stale
Updated 22mo ago
| NCT05578976 |
| InnoBM Pharmaceuticals Co., Ltd. | A Clinical Trial Assessing the Safety and Efficacy of Biodegradable Magnesium Embolic Microspheres for Primary Hepatocellular Carcinoma | Hepatocellular Carcinoma Non-Resectable | Not Yet Recruiting | Q2 2027 2027-06 (est.) | Estimated · stale
Updated 22mo ago
| NCT06779461 |
| Changchun GeneScience Pharmaceutic… | Nano-crystalline Megestrol Acetate for Adjuvant Treatment in High-risk Head and Neck Squamous Cell Carcinoma After Surgery. Asset: Nano-crystalline Megestrol Acetate Oral Suspension | Head and Neck Squamous Cell Carcinoma; Underwent Surgery Within 6 Weeks and Postoperative Assessment Indicated High-risk Factors | Not Yet Recruiting | Q2 2027 2027-06-30 (est.) | Estimated · stale
Updated 22mo ago
| NCT06772428 |
| Jiangsu HengRui Medicine Co., Ltd. | SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen Asset: SHR-A1811 | HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma | Recruiting | Q2 2027 2027-06-30 (est.) | Estimated · stale
Updated 34mo ago
| NCT06123494 |
| Shanghai Yizhong Pharmaceutical Co… | Polymeric Micellar Paclitaxel for Metastatic Pancreatic Cancer | Pancreatic Cancer Metastatic | Recruiting | Q3 2027 2027-07-01 (est.) | Estimated · aging
Updated 9mo ago
| NCT06752811 |
| Shijiazhuang Yiling Pharmaceutical… | A Study of XY0206 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory AML With FLT3-ITD-Mutation (ALIVE) Asset: XY0206 | Acute Myeloid Leukemia With FLT3/ITD Mutation | Not Yet Recruiting | Q3 2027 2027-07-01 (est.) | Estimated · stale
Updated 42mo ago
| NCT05876832 |
| Amgen | Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab Asset: Tarlatamab | Extensive-Stage Small-Cell Lung Cancer +1 | Active Not Recruiting | Q3 2027 2027-07-05 (est.) | Estimated · aging
Updated 11mo ago
| NCT06211036 |
| Merck Sharp & Dohme LLC | A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) Asset: Sacituzumab tirumotecan | Breast Neoplasms | Recruiting | Q3 2027 2027-07-11 (est.) | Estimated · aging
Updated 7mo ago
| NCT06312176 |
| AstraZeneca | A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Asset: Acalabrutinib | Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | Active Not Recruiting | Q3 2027 2027-07-15 (est.) | Estimated · aging
Updated 9mo ago
| NCT05057494 |
| Pfizer | A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. Asset: PF-07248144 | Breast Cancer | Recruiting | Q3 2027 2027-07-22 (est.) | Estimated · aging
Updated 7mo ago
| NCT07062965 |
| AstraZeneca | A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05) Asset: Dato-DXd | Breast Cancer | Recruiting | Q3 2027 2027-07-28 (est.) | Estimated · aging
Updated 7mo ago
| NCT06103864 |
| Genmab | Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06) Asset: Acasunlimab | PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC | Active Not Recruiting | Q3 2027 2027-07-30 (est.) | Estimated · aging
Updated 7mo ago
| NCT06635824 |
| Bayer | A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies | Biochemically Recurrent Prostate Cancer | Active Not Recruiting | Q3 2027 2027-07-30 (est.) | Estimated · aging
Updated 7mo ago
| NCT05794906 |
| Janssen Research & Development, LLC | A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment Asset: Talquetamab | Multiple Myeloma | Active Not Recruiting | Q3 2027 2027-07-30 (est.) | Estimated · aging
Updated 7mo ago
| NCT05455320 |
| Shanghai Bovax Biotechnology Co., … | A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males Asset: 9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52 and 58) Recombinant Vaccine (Hansenula Polymorpha) | Genital Wart +9 | Active Not Recruiting | Q3 2027 2027-07-30 (est.) | Estimated · stale
Updated 23mo ago
| NCT06465914 |
| Sichuan Kelun-Biotech Biopharmaceu… | A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy Asset: SKB264 | Metastatic Breast Cancer | Recruiting | Q3 2027 2027-07 (est.) | Estimated · aging
Updated 11mo ago
| NCT07071337 |
| Telix Pharmaceuticals (Innovations… | Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma | Neoplastic Disease +5 | Recruiting | Q3 2027 2027-07 (est.) | Estimated · aging
Updated 7mo ago
| NCT07100730 |
| Sinocelltech Ltd. | A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer. Asset: SCTB14 | Non-Small Cell Lung Carcinoma (NSCLC) | Recruiting | Q3 2027 2027-07 (est.) | Estimated · aging
Updated 10mo ago
| NCT07362459 |
| Maia Biotechnology | A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC Asset: 6-Thio-2'-Deoxyguanosine | Carcinoma, Non-Small -Cell Lung | Recruiting | Q3 2027 2027-07-31 (est.) | Estimated · aging
Updated 10mo ago
| NCT06908304 |
| Shanghai Henlius Biotech | A Study to Evaluate the Efficacy and Safety of HLX15-IV Versus DARZALEX® in Combination with Lenalidomide-Dexamethasone (Rd) in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma Asset: HLX15-IV | Newly Diagnosed Multiple Myeloma | Not Yet Recruiting | Q3 2027 2027-07 (est.) | Estimated · stale
Updated 20mo ago
| NCT06895512 |
| Biotheus Inc. | PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC Asset: PM8002 | Triple Negative Breast Cancer(TNBC) | Active Not Recruiting | Q3 2027 2027-07 (est.) | Estimated · stale
Updated 20mo ago
| NCT06419621 |
| AstraZeneca | A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection Asset: Osimertinib | Non-Small Cell Lung Cancer | Active Not Recruiting | Q3 2027 2027-08-02 (est.) | Estimated · aging
Updated 7mo ago
| NCT05120349 |
| Pfizer | Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant Asset: Elranatamab | Multiple Myeloma | Active Not Recruiting | Q3 2027 2027-08-04 (est.) | Estimated · aging
Updated 7mo ago
| NCT05317416 |
| SOFIE | Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer. Asset: [18F]FAPI-74 PET/CT | Esophageal Cancer +2 | Recruiting | Q3 2027 2027-08-30 (est.) | Estimated · aging
Updated 7mo ago
| NCT07217704 |
| AbbVie | An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Asset: Venetoclax | Chronic Lymphocytic Leukemia +5 | Active Not Recruiting | Q3 2027 2027-08 (est.) | Estimated · aging
Updated 8mo ago
| NCT03844048 |
| Hoffmann-La Roche | A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma Asset: Obinutuzumab | Lymphoma | Recruiting | Q3 2027 2027-08-31 (est.) | Estimated · aging
Updated 7mo ago
| NCT06084936 |
| Crinetics Pharmaceuticals Inc. | Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen Asset: Paltusotine | Carcinoid Syndrome +8 | Active Not Recruiting | Q3 2027 2027-08 (est.) | Estimated · aging
Updated 8mo ago
| NCT07087054 |
| OncoC4, Inc. | ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors Asset: Gotistobart | Non Small Cell Lung Cancer | Active Not Recruiting | Q3 2027 2027-08-31 (est.) | Estimated · aging
Updated 7mo ago
| NCT05671510 |
| AVEO Pharmaceuticals, Inc. | A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma Asset: Ficlatuzumab | Metastatic Head-and-neck Squamous-cell Carcinoma +1 | Recruiting | Q3 2027 2027-08 (est.) | Estimated · aging
Updated 7mo ago
| NCT06064877 |
| Telix Pharmaceuticals (Innovations… | Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC | ccRCC +5 | Recruiting | Q3 2027 2027-08-31 (est.) | Estimated · aging
Updated 7mo ago
| NCT07197580 |
| Chia Tai Tianqing Pharmaceutical G… | A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxaliplatin, Irinotecan and Fluoropyrimidine-Based Drugs Asset: TQB2102 Injection | HER2 IHC3+ Advanced Colorectal Cancer | Not Yet Recruiting | Q3 2027 2027-08 (est.) | Estimated · aging
Updated 8mo ago
| NCT07483684 |
| Nanjing IASO Biotechnology Co., Ltd. | A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03) Asset: Equecabtagene Autoleucel Injection | Multiple Myeloma | Active Not Recruiting | Q3 2027 2027-08 (est.) | Estimated · stale
Updated 16mo ago
| NCT06464991 |
| Qilu Pharmaceutical Co., Ltd. | A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection. Asset: QL1706 injection | Carcinoma, Non-Small-Cell Lung | Recruiting | Q3 2027 2027-08-31 (est.) | Estimated · stale
Updated 25mo ago
| NCT05487391 |
| Ascentage Pharma Group Inc. | A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL. Asset: Lisaftoclax (APG-2575) | CLL/SLL | Recruiting | Q3 2027 2027-08 (est.) | Estimated · stale
Updated 30mo ago
| NCT06319456 |
| Lee's Pharmaceutical Limited | Phase III Study of Socazolimab as First-Line Treatment in Persistent, Recurrent, or Metastatic Cervical Cancer Asset: Socazolimab+cisplatin/carboplatin+paclitaxel+Bevacizumab | Cervical Cancer | Recruiting | Q3 2027 2027-09-01 (est.) | Estimated · stale
Updated 18mo ago
| NCT06459687 |
| Qilu Pharmaceutical Co., Ltd. | A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma Asset: QL1706 | Hepatocellular Carcinoma | Not Yet Recruiting | Q3 2027 2027-09-01 (est.) | Estimated · stale
Updated 39mo ago
| NCT05976568 |
| Celgene | A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer Asset: BMS-986365 | Metastatic Castration-resistant Prostate Cancer | Active Not Recruiting | Q3 2027 2027-09-12 (est.) | Estimated · aging
Updated 9mo ago
| NCT06764485 |
| Shanghai Bovax Biotechnology Co., … | Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females Asset: 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha) | Cervical Cancer +13 | Recruiting | Q3 2027 2027-09-15 (est.) | Estimated · stale
Updated 29mo ago
| NCT04422366 |
| AstraZeneca | A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03) Asset: Dato-DXd | Breast Cancer | Active Not Recruiting | Q3 2027 2027-09-20 (est.) | Estimated · aging
Updated 8mo ago
| NCT05629585 |
| Shanghai Kechow Pharma, Inc. | Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma Asset: tunlametinib | Melanoma | Recruiting | Q3 2027 2027-09-22 (est.) | Estimated · stale
Updated 29mo ago
| NCT06008106 |
| Merck Sharp & Dohme LLC | A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) Asset: Zilovertamab vedotin | DLBCL +1 | Recruiting | Q3 2027 2027-09-24 (est.) | Estimated · aging
Updated 7mo ago
| NCT05139017 |
| Hoffmann-La Roche | A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer Asset: Divarasib | Non-Small Cell Lung Cancer +1 | Active Not Recruiting | Q3 2027 2027-09-30 (est.) | Estimated · aging
Updated 7mo ago
| NCT06497556 |
| Chia Tai Tianqing Pharmaceutical G… | A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Asset: TQB2102 for injection | HER2-positive Breast Cancer | Recruiting | Q3 2027 2027-09 (est.) | Estimated · aging
Updated 8mo ago
| NCT07043725 |
| Suzhou Suncadia Biopharmaceuticals… | A Trial of SHR-A2102 With Adebrelimab in Locally Advanced or Metastatic Urothelial Carcinoma Asset: SHR-A2102 and Adebrelimab | Locally Advanced or Metastatic Urothelial Carcinoma | Recruiting | Q3 2027 2027-09 (est.) | Estimated · aging
Updated 8mo ago
| NCT07393542 |
| Keymed Biosciences Co.Ltd | Study of CM336 in Relapsed or Refractory Multiple Myeloma Patients Asset: CM336 Injection | Multiple Myeloma (MM) | Not Yet Recruiting | Q3 2027 2027-09 (est.) | Estimated · stale
Updated 14mo ago
| NCT07181239 |
| PharmaEssentia | P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk Asset: Ropeginterferon alfa-2b | Primary Myelofibrosis +1 | Active Not Recruiting | Q3 2027 2027-09-30 (est.) | Estimated · stale
Updated 15mo ago
| NCT06468033 |
| Mabwell (Shanghai) Bioscience Co.,… | 9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer Asset: 9MW2821 | Urothelial Carcinoma | Recruiting | Q3 2027 2027-09 (est.) | Estimated · stale
Updated 26mo ago
| NCT06592326 |
| Daiichi Sankyo | Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer Asset: Trastuzumab Deruxtecan | Breast Cancer | Recruiting | Q4 2027 2027-10-01 (est.) | Estimated · aging
Updated 7mo ago
| NCT05950945 |
| Hoffmann-La Roche | An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma Asset: Glofitamab | Large B-Cell Lymphoma | Active Not Recruiting | Q4 2027 2027-10-01 (est.) | Estimated · aging
Updated 8mo ago
| NCT06047080 |
| Immunocore Ltd | IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) Asset: Brenetafusp | Advanced Melanoma | Recruiting | Q4 2027 2027-10-16 (est.) | Estimated · aging
Updated 9mo ago
| NCT06112314 |
| Bayer | A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) Asset: Sevabertinib | Advanced Non-small Cell Lung Cancer, HER2 Mutation | Recruiting | Q4 2027 2027-10-28 (est.) | Estimated · aging
Updated 7mo ago
| NCT06452277 |
| Merck Sharp & Dohme LLC | Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013) Asset: Pembrolizumab 200 mg | Small Cell Lung Cancer | Active Not Recruiting | Q4 2027 2027-10-28 (est.) | Estimated · stale
Updated 16mo ago
| NCT04624204 |
| BeOne Medicines | A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Asset: Subcutaneous Tislelizumab | Metastatic Gastric Adenocarcinoma +1 | Recruiting | Q4 2027 2027-10-30 (est.) | Estimated · aging
Updated 7mo ago
| NCT07043400 |
| Hoffmann-La Roche | A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer) Asset: Phesgo | Locally Advanced or Metastatic Breast Cancer | Active Not Recruiting | Q4 2027 2027-10-31 (est.) | Estimated · aging
Updated 7mo ago
| NCT05296798 |
| J-Pharma Co., Ltd. | A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer Asset: Nanvuranlat | Advanced Biliary Tract Cancer +1 | Recruiting | Q4 2027 2027-10 (est.) | Estimated · aging
Updated 7mo ago
| NCT07265674 |
| Eli Lilly and Company | A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer Asset: Imlunestrant | Breast Neoplasms | Active Not Recruiting | Q4 2027 2027-10 (est.) | Estimated · aging
Updated 7mo ago
| NCT05514054 |
| Jiangsu HengRui Medicine Co., Ltd. | A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer Asset: SHR-A1811 Injection | HER2-PositiveRecurrent or Metastatic Breast Cancer | Active Not Recruiting | Q4 2027 2027-10 (est.) | Estimated · aging
Updated 8mo ago
| NCT06057610 |
| Quercis Pharma AG | The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer Asset: Kinisoquin™ | Venous Thromboembolism +2 | Recruiting | Q4 2027 2027-10-31 (est.) | Estimated · aging
Updated 9mo ago
| NCT06861088 |
| Guangzhou JOYO Pharma Co., Ltd | JYP0322 Versus Platinum Based Doublet Chemotherapy in ROS1 Positive Patients Previously Treated With ROS1-TKIs. Asset: Pemetrexed injection | Non Small Cell Lung Cancer | Not Yet Recruiting | Q4 2027 2027-10-31 (est.) | Estimated · stale
Updated 14mo ago
| NCT07154368 |
| Jiangsu Aosaikang Pharmaceutical C… | ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy Asset: ASKC202+ Limertinib | Locally Advanced or Metastatic NSCLC | Recruiting | Q4 2027 2027-10-31 (est.) | Estimated · stale
Updated 15mo ago
| NCT07109531 |
| Acacia Pharma Ltd | Investigation of Remimazolam in Children Undergoing Sedation for Medical Procedures Asset: Remimazolam | Pediatric ALL | Active Not Recruiting | Q4 2027 2027-10 (est.) | Estimated · stale
Updated 16mo ago
| NCT04851717 |
| Chengdu New Radiomedicine Technolo… | Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere Asset: NRT6003 Injection | Unresectable Hepatocellular Carcinoma | Active Not Recruiting | Q4 2027 2027-10 (est.) | Estimated · stale
Updated 18mo ago
| NCT06900543 |
| Taiho Oncology, Inc. | A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study) Asset: Azacitidine | Myelodysplastic Syndromes +3 | Recruiting | Q4 2027 2027-11-01 (est.) | Estimated · aging
Updated 7mo ago
| NCT04256317 |
| AstraZeneca | Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations Asset: Datopotamab deruxtecan | NSCLC | Active Not Recruiting | Q4 2027 2027-11-01 (est.) | Estimated · aging
Updated 7mo ago
| NCT05687266 |
| AstraZeneca | Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292) Asset: Capivasertib | Locally Advanced (Inoperable) or Metastatic Breast Cancer | Active Not Recruiting | Q4 2027 2027-11-01 (est.) | Estimated · aging
Updated 7mo ago
| NCT04862663 |
| GlaxoSmithKline | A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301] Asset: Risvutatug rezetecan (Ris-Rez) | Neoplasms, Lung | Recruiting | Q4 2027 2027-11-05 (est.) | Estimated · aging
Updated 7mo ago
| NCT07099898 |
Unlock 212 more oncology readouts · plus filters on the full calendar
About this calendar
Dates anchor on the ClinicalTrials.gov primary completion date — the only public, structured signal — and are graded by date type (actual vs sponsor-estimated) and how recently the record was updated. Sponsor-estimated dates can slip silently, so treat each as a current target rather than a guarantee. See the full readout calendar for all areas and filters.